Description: Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Home Page: eliemtx.com
PMB #117, 2801 Centerville Road
Wilmington,
DE
19808-1609
United States
Phone:
866 857 2596
Officers
| Name | Title |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | CEO, President & Director |
| Dr. Brett Kaplan M.B.A., M.D. | COO & Principal Financial Officer |
| Ms. Emily Pimblett | Chief Accounting Officer |
| Ms. Jo Palmer-Phillips Ph.D. | Chief Development Officer |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |